Skip to contentS
Skye Bioscience, Inc.
S
SKYESkye Bioscience, Inc. Released Mar 20, 2020, after the close
10-K filed Mar 23, 2020, 83 days after period end · 0001640334-20-000582
Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income$4.85M$4.85Mderived
No earnings release is on file for this quarter. Its figures came with the 10-K.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR
N/M vs Q3 2019
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$1,843,510N/M Operating Cash Flowderived-$1,503,229N/M ended Dec 31, 2019 · filed Mar 23, 2020 · 83 d after period end